VACCINE USAGE: A single dose of KINRIX® is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) and/or PEDIARIX® [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] for the first three doses and INFANRIX for the fourth dose.
VACCINE DOSAGE: KINRIX is to be administered as a 0.5-mL dose by intramuscular injection. The preferred site of administration is the deltoid muscle of the upper arm.
KINRIX may be used for the fifth dose in the DTaP immunization series and the fourth dose in the IPV immunization series in children 4 through 6 years of age (prior to the seventh birthday) whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose.
VACCINE INGEDIENTS: formaldehyde, glutaraldehyde, aluminum hydroxide, vero (monkey kidney) cells, calf serum, lactalbumin hydrolysate, polysorbate 80, neomycin sulfate, polymyxin B, Fenton medium (containing bovine extract), modified Latham medium (derived from bovine casein), modified Stainer-Scholte liquid medium.
ADVERSE VACCINE REACTIONS: temp above 105 degrees, collapse or shock-like state, persistent/ inconsolable crying lasting more than 3 hours, seizures with or without fever, cellulitis, constipation, foreign body trauma, injection site vesicles, syncope, anaphylactoid reactions, anaphylaxis, angioedema, urticaria, apnea, lymphadenopathy, thrombocytopenia.